Advancing Discoveries in Fibrosis

Posters & Presentations

• Post-hoc biomarker analysis in participants with IPF receiving bexotegrast over 12-weeks in INTEGRIS-IPF
  
• (Oral Presentation) Safety and tolerability of bexotegrast in Phase 2 trials of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC)
  
• Safety and tolerability of bexotegrast in Phase 2 trials of idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC)
  
• (Oral Presentation) Bexotegrast reduces type 1 collagen deposition in participants with idiopathic pulmonary fibrosis (IPF) after 12 weeks of therapy
  
• Bexotegrast reduces type 1 collagen deposition in participants with idiopathic pulmonary fibrosis (IPF) after 12 weeks of therapy
  
• Evaluation of the antifibrotic activity of bexotegrast, a dual αVβ6/αVβ1 integrin inhibitor, in precision cut-lung slices prepared from non-IPF interstitial lung disease explants
  
• Dual alpha-v/beta-6 and alpha-v/beta-1 integrin inhibitor bexotegrast targets TGF-beta inhibition to specific cell types in human liver explant tissue with biliary fibrosis
  
• Oral alpha-v/beta-6 and alpha-v/beta-1 integrin inhibitor bexotegrast in primary sclerosing cholangitis: Updated 12-week interim safety and efficacy analysis of the INTEGRIS-PSC Phase 2a trial
  
• (Oral Presentation) Update on the safety and tolerability of bexotegrast, a dual-selective inhibitor of integrins αvβ6 and αvβ1, in development for idiopathic pulmonary fibrosis and primary sclerosing cholangitis
  
• (E-Poster) Update on the safety and tolerability of bexotegrast, a dual-selective inhibitor of integrins αvβ6 and αvβ1, in development for idiopathic pulmonary fibrosis and primary sclerosing cholangitis
  
• Evaluation of quantitative imaging in a Phase 2a study for the treatment of idiopathic pulmonary fibrosis with bexotegrast (INTEGRIS-IPF)
  
• Bexotegrast targets TGF-beta inhibition to specific cell types in the fibrotic human lung
  
• Post-hoc Analysis of Biomarkers of Interstitial Lung Disease Progression in Participants with Idiopathic Pulmonary Fibrosis Receiving Bexotegrast Over 12-weeks in INTEGRIS-IPF
  
• Oral α_vβ₆/α_vβ₁ Integrin Inhibition in Primary Sclerosing Cholangitis: 12-week Interim Safety and Efficacy Analysis of INTEGRIS-PSC, A Phase 2a Trial of Bexotegrast
  
• Inhibition of integrin α_Vβ₁ attenuates profibrogenic gene expression by myofibroblasts in fibrotic human liver explants
  
• Dual α_Vβ₆/α_Vβ₁ integrin inhibitor bexotegrast attenuates profibrogenic gene expression across multiple pathologic cell types in human liver explant tissue with biliary fibrosis
  
• Oral α_Vβ₆/α_Vβ₁ integrin inhibition in primary sclerosing cholangitis: 12-week interim safety and efficacy analysis of INTEGRIS-PSC, a phase 2a trial of bexotegrast
  
• Phase 1a trial of PLN-101095, an integrin α_vβ₈ and α_vβ₁ inhibitor, as monotherapy and in combination with pembrolizumab, in treatment-resistant patients with advanced or metastatic solid tumors
  
• Integrin α_vβ₁ is expressed in multiple solid tumors and drives the adhesion of cancer-associated fibroblasts to latent TGF-β
  
• Selective targeting of integrins α_Vß₈ and α_Vß₁ within the dynamic ecosystem of pancreatic cancer to improve overall anti-tumor response
  
• Safety, Tolerability and Antifibrotic Activity of Bexotegrast: Phase 2a INTEGRIS-IPF Study (NCT04396756)
  
• Circulating ITGB6 Levels Are Elevated in Patients with Idiopathic Pulmonary Fibrosis and Reduced Following Lung Transplant
  
• Dual α_vβ₆/α_vβ₁ Integrin Inhibitor Bexotegrast Reduces Fibrogenesis in Pathological Cell Populations Present in the Fibrotic Human Lung
  
• INTEGRIS-PSC Phase 2a Study: Evaluating the Safety, Tolerability, and Pharmacokinetics of Bexotegrast (PLN-74809) in Participants with Primary Sclerosing Cholangitis
  
• Dual alpha-v/beta-6 and alpha-v/beta-1 Integrin Inhibitor Bexotegrast Attenuates Profibrogenic Gene Expression of Myofibroblasts in Human Liver Explant Tissue with Biliary Fibrosis
  
• Non-invasive Imaging Method Demonstrates Anti-fibrotic Efficacy of a Dual Integrin alpha-v/beta-6 and alpha-v/beta-1 Inhibitor in a Rat Model of Biliary Fibrosis
  
• Single nuclei RNA-seq profiling of fibrotic human precision-cut tissue slices: a model for evaluating anti-fibrotic therapies in lung and liver
  
• Dual α_Vβ₆/α_Vβ₁ Integrin Inhibitor PLN-74809 Attenuates Pathologic Fibroblasts in Human Fibrotic Lung Explant Tissue
  
• PLN-74809 Shows Favorable Safety and Tolerability and Indicates Antifibrotic Activity in a Phase 2a Study for the Treatment of Idiopathic Pulmonary Fibrosis
  
• INTEGRIS-PSC Phase 2a Study: Evaluating the Safety, Tolerability, and Pharmacokinetics of Bexotegrast (PLN-74809) in Participants with Primary Sclerosing Cholangitis
  
• Dual alpha-v/beta-6 and alpha-v/beta-1 Integrin Inhibitor Bexotegrast Attenuates Profibrogenic Gene Expression of Myofibroblasts in Human Liver Explant Tissue with Biliary Fibrosis
  
• Non-invasive Imaging Method Demonstrates Anti-fibrotic Efficacy of a Dual Integrin alpha-v/beta-6 and alpha-v/beta-1 Inhibitor in a Rat Model of Biliary Fibrosis
  
• Combining Dual α_Vβ₆/α_Vβ₁ Integrin Inhibitor, PLN-74809, With Standard-of-Care Therapies Has a Synergistic Effect on Reducing Fibrogenic Gene Expression in Fibrotic Human Lung Slices
  
• PLN-74809, A dual-selective inhibitor of integrins α_vβ₆ and α_vβ₁ shows dose-dependent target engagement in the lungs of patients with idiopathic pulmonary fibrosis (IPF)
  
• PLN-74809, an oral, dual-selective α_vβ₆/α_vβ₁ inhibitor in phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF), sustainably reduces transforming growth factor-beta (TGF-β) activity in the lungs of healthy participants with once-daily dosing
  
• PLN-74809, a dual-selective inhibitor of α_vβ₆ and α_vβ₁, is well tolerated in over 280 healthy participants
  
• Therapeutic biomarker discovery in idiopathic pulmonary fibrosis (IPF) through proteomic analysis of precision-cut lung slice (PCLS) supernatants
  
• Pharmacological inhibitors of integrin α_vβ₆ that differentially modulate protein conformation are similarly effective at inhibiting TGF-β signaling in the fibrotic lung
  
• Profiling fibrosis regression in a rat model of non-alcoholic steatohepatitis
  
• PK/PD assessment of an oral, selective α_Vβ₆ /α_Vβ₁ integrin dual antagonist, PLN-74809, for the treatment of idiopathic pulmonary fibrosis
  
• Dual α_Vβ₆ /α_Vβ₁ inhibitor PLN-74809 blocks multiple TGF-β activation pathways associated with IPF
  
• PLN-74809, a dual α_Vβ₆/α_Vβ₁ integrin inhibitor, inhibits fibrosis in precision-cut liver tissue from PSC and PBC patients and the Mdr2 knockout mouse
  
• PLN-74809, a dual α_vβ₆/α_vβ₁, oral, selective integrin inhibitor, is well tolerated and reduces lung TGF-β activity in healthy volunteers
  
• Selective Small Molecule Inhibitor of Integrin α_vβ₈ and α_vβ₁ Has Single Agent Activity and Potentiates Immune Checkpoint Blockade Therapy